{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:50:29Z","timestamp":1791453029059,"version":"4.3.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01896-7","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:21:38Z","timestamp":1790871698000},"page":"4873-4886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OX40 Ligand\/OX40 Axis as the Inflammatory Prequel in Atopic Dermatitis: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1515","authenticated-orcid":false,"given":"Shawn G.","family":"Kwatra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3260-9630","authenticated-orcid":false,"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-4445","authenticated-orcid":false,"given":"Bob","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7371-4509","authenticated-orcid":false,"given":"Ahmed","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-509X","authenticated-orcid":false,"given":"Nicolas","family":"Gaudenzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6700-9171","authenticated-orcid":false,"given":"Kassim","family":"Rahawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Hui","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"10247","key":"1896_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"3","key":"1896_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, et al. OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol. 2024;25(3):447\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1896_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1896_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1896_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1896_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84(11):1379\u201394.","journal-title":"Drugs"},{"key":"1896_CR7","unstructured":"Levine J, Mehta A, O\u2019Hagan R, Guttman-Yassky E, Lamb AJ. Decision-making factors for systemic therapies in atopic dermatitis: a clinical review. Dermatitis. 2026:17103568261423754."},{"issue":"4","key":"1896_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjd\/ljae230","volume":"191","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Croft M, Geng B, Rynkiewicz N, Lucchesi D, Peakman M, et al. The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024;191(4):488\u201396.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1896_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/cells13070587","volume":"13","author":"K Sadrolashrafi","year":"2024","unstructured":"Sadrolashrafi K, Guo L, Kikuchi R, Hao A, Yamamoto RK, Tolson HC, et al. An OX-tra\u2019ordinary tale: the role of OX40 and OX40L in atopic dermatitis. Cells. 2024;13(7):587.","journal-title":"Cells"},{"issue":"4","key":"1896_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264\u201375.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1896_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s13555-025-01609-6","volume":"16","author":"A Reich","year":"2026","unstructured":"Reich A, Blauvelt A, Weidinger S, Shi VY, Katoh N, Lynde C, et al. A post hoc analysis of atopic dermatitis of the head and neck and other body regions from the amlitelimab STREAM-AD phase 2b study. Dermatol Ther. 2026;16(1):605\u201316.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1896_CR12","first-page":"117","volume":"26","author":"W Tuerdebieke","year":"2026","unstructured":"Tuerdebieke W, Zhuo-wei L, Shi-xiong S, Lin J, Ming C, Xin Z, et al. Research progress on the mechanisms of OX40\/OX40L signaling pathway in regulating inflammatory prequel-inflammation transition and targeted therapy of diseases. Prog Mod Biomed. 2026;26(1):117\u201331.","journal-title":"Prog Mod Biomed"},{"issue":"3","key":"1896_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","volume":"10","author":"BE Kim","year":"2018","unstructured":"Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207\u201315.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"10478","key":"1896_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583\u201396.","journal-title":"Lancet"},{"issue":"3","key":"1896_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/000155500750042943","volume":"80","author":"B Eberlein-K\u00f6nig","year":"2000","unstructured":"Eberlein-K\u00f6nig B, Sch\u00e4fer T, Huss-Marp J, Darsow U, M\u00f6hrenschlager M, Herbert O, et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. Acta Derm Venereol. 2000;80(3):188\u201391.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1896_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1600-0846.1999.tb00134.x","volume":"5","author":"A Sparavigna","year":"1999","unstructured":"Sparavigna A, Setaro M, Gualandri V. Cutaneous pH in children affected by atopic dermatitis and in healthy children: a multicenter study. Skin Res Technol. 1999;5(4):221\u20137.","journal-title":"Skin Res Technol"},{"issue":"6","key":"1896_CR17","first-page":"359","volume":"96","author":"NB Silverberg","year":"2015","unstructured":"Silverberg NB, Silverberg JI. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. 2015;96(6):359\u201361.","journal-title":"Cutis"},{"key":"1896_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1239251","volume":"14","author":"Y Hatano","year":"2023","unstructured":"Hatano Y, Elias PM. \u201cOutside-to-inside,\u201d \u201cinside-to-outside,\u201d and \u201cintrinsic\u201d endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023;14:1239251.","journal-title":"Front Immunol"},{"issue":"7","key":"1896_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ni805","volume":"3","author":"V Soumelis","year":"2002","unstructured":"Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673\u201380.","journal-title":"Nat Immunol"},{"issue":"1","key":"1896_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"1896_CR21","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.3390\/ijms23126682","volume":"23","author":"R Tanei","year":"2022","unstructured":"Tanei R, Hasegawa Y. Immunological pathomechanisms of spongiotic dermatitis in skin lesions of atopic dermatitis. Int J Mol Sci. 2022;23(12):6682.","journal-title":"Int J Mol Sci"},{"issue":"8112","key":"1896_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s41586-026-10162-x","volume":"652","author":"Y Xing","year":"2026","unstructured":"Xing Y, Reznikov I, Ahmed AN, Sidhu I, Wisnewski J, Farhat A, et al. Peripheral immune-inducer dendritic cells drive early-life allergic inflammation. Nature. 2026;652(8112):1308\u201317.","journal-title":"Nature"},{"issue":"3","key":"1896_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2332\/allergolint.13-OA-0672","volume":"63","author":"N Murakami-Satsutani","year":"2014","unstructured":"Murakami-Satsutani N, Ito T, Nakanishi T, Inagaki N, Tanaka A, Vien PT, et al. IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int. 2014;63(3):443\u201355.","journal-title":"Allergol Int"},{"key":"1896_CR24","doi-asserted-by":"publisher","first-page":"1342176","DOI":"10.3389\/fmed.2024.1342176","volume":"11","author":"Y Yamamura","year":"2024","unstructured":"Yamamura Y, Nakashima C, Otsuka A. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from murin models and human. Front Med (Lausanne). 2024;11:1342176.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1896_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.berh.2009.12.015","volume":"24","author":"AM Gizinski","year":"2010","unstructured":"Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010;24(4):463\u201377.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"1896_CR26","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI33559","volume":"117","author":"D Seshasayee","year":"2007","unstructured":"Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest. 2007;117(12):3868\u201378.","journal-title":"J Clin Invest"},{"issue":"4","key":"1896_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jid.2022.11.009","volume":"143","author":"H Iriki","year":"2023","unstructured":"Iriki H, Takahashi H, Amagai M. Diverse role of OX40 on T cells as a therapeutic target for skin diseases. J Invest Dermatol. 2023;143(4):545\u201353.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1896_CR28","doi-asserted-by":"publisher","first-page":"adv00099","DOI":"10.2340\/00015555-3452","volume":"100","author":"JS Elsner","year":"2020","unstructured":"Elsner JS, Carlsson M, Stougaard JK, Nygaard U, Buchner M, F\u00f6lster-Holst R, et al. The OX40 axis is associated with both systemic and local involvement in atopic dermatitis. Acta Derm Venereol. 2020;100(6):adv00099.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1896_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","volume":"43","author":"H Hammad","year":"2015","unstructured":"Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29\u201340.","journal-title":"Immunity"},{"issue":"3","key":"1896_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020;10(3):414\u201333.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"1896_CR31","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/jcm10122578","volume":"10","author":"M Furue","year":"2021","unstructured":"Furue M, Furue M. OX40L-OX40 signaling in atopic dermatitis. J Clin Med. 2021;10(12):2578.","journal-title":"J Clin Med"},{"issue":"2","key":"1896_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2015.06.023","volume":"43","author":"GD Sckisel","year":"2015","unstructured":"Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, et al. Out-of-sequence signal 3 paralyzes primary CD4(+) T-cell-dependent immunity. Immunity. 2015;43(2):240\u201350.","journal-title":"Immunity"},{"issue":"6","key":"1896_CR33","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.4049\/jimmunol.165.6.3043","volume":"165","author":"I Gramaglia","year":"2000","unstructured":"Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165(6):3043\u201350.","journal-title":"J Immunol"},{"issue":"3","key":"1896_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2011.05.016","volume":"128","author":"H Fujita","year":"2011","unstructured":"Fujita H, Shemer A, Su\u00e1rez-Fari\u00f1as M, Johnson-Huang LM, Tintle S, Cardinale I, et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. J Allergy Clin Immunol. 2011;128(3):574-82.e1-12.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1896_CR35","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","volume":"161","author":"I Gramaglia","year":"1998","unstructured":"Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 1998;161(12):6510\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"1896_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"M Croft","year":"2009","unstructured":"Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229(1):173\u201391.","journal-title":"Immunol Rev"},{"issue":"3","key":"1896_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","volume":"15","author":"PR Rogers","year":"2001","unstructured":"Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15(3):445\u201355.","journal-title":"Immunity"},{"key":"1896_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1473815","volume":"15","author":"A Sato","year":"2024","unstructured":"Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N, et al. Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-lymphocytes. Front Immunol. 2024;15:1473815.","journal-title":"Front Immunol"},{"issue":"5","key":"1896_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.immuni.2005.03.012","volume":"22","author":"J Song","year":"2005","unstructured":"Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity. 2005;22(5):621\u201331.","journal-title":"Immunity"},{"issue":"1","key":"1896_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2006.04.001","volume":"106","author":"T Fujita","year":"2006","unstructured":"Fujita T, Ukyo N, Hori T, Uchiyama T. Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett. 2006;106(1):27\u201333.","journal-title":"Immunol Lett"},{"issue":"2","key":"1896_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/all.70060","volume":"81","author":"P D\u2019Avino","year":"2026","unstructured":"D\u2019Avino P, Kim J, Li M, Gessner P, Westermann P, Pat Y, et al. Distinct roles of IL-4, IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis. Allergy. 2026;81(2):480\u201397.","journal-title":"Allergy"},{"issue":"4","key":"1896_CR42","doi-asserted-by":"publisher","first-page":"e98006","DOI":"10.1172\/jci.insight.98006","volume":"3","author":"E Berdyshev","year":"2018","unstructured":"Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018;3(4):e98006.","journal-title":"JCI Insight"},{"issue":"11","key":"1896_CR43","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/jid.2008.111","volume":"128","author":"C Koga","year":"2008","unstructured":"Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625\u201330.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1896_CR44","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","volume":"181","author":"E Guttman-Yassky","year":"2008","unstructured":"Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008;181(10):7420\u20137.","journal-title":"J Immunol"},{"issue":"2","key":"1896_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2013","unstructured":"Su\u00e1rez-Fari\u00f1as M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361\u201370.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1896_CR46","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","volume":"138","author":"H Esaki","year":"2016","unstructured":"Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639\u201351.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1896_CR47","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.4049\/jimmunol.1600126","volume":"198","author":"H Lou","year":"2017","unstructured":"Lou H, Lu J, Choi EB, Oh MH, Jeong M, Barmettler S, et al. Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway. J Immunol. 2017;198(7):2543\u201355.","journal-title":"J Immunol"},{"issue":"7","key":"1896_CR48","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2007-01-070748","volume":"110","author":"MD Vu","year":"2007","unstructured":"Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110(7):2501\u201310.","journal-title":"Blood"},{"issue":"3","key":"1896_CR49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.celrep.2018.06.052","volume":"24","author":"X Zhang","year":"2018","unstructured":"Zhang X, Xiao X, Lan P, Li J, Dou Y, Chen W, et al. OX40 costimulation inhibits Foxp3 expression and Treg induction via BATF3-dependent and independent mechanisms. Cell Rep. 2018;24(3):607\u201318.","journal-title":"Cell Rep"},{"issue":"2","key":"1896_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021937","volume":"198","author":"S Salek-Ardakani","year":"2003","unstructured":"Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, Yagita H, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med. 2003;198(2):315\u201324.","journal-title":"J Exp Med"},{"issue":"3","key":"1896_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jaci.2016.06.003","volume":"138","author":"M Noval Rivas","year":"2016","unstructured":"Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016;138(3):639\u201352.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1896_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.alit.2026.02.004","volume":"75","author":"YJ Bang","year":"2026","unstructured":"Bang YJ, Lee BH, Jeong S, Moon Y, Lee JH, Kim-Schulze S, et al. High-dimensional immune profiling of atopic dermatitis reveals a dysfunctional OX40(+) regulatory T cell subset. Allergol Int. 2026;75(3):488\u201399.","journal-title":"Allergol Int"},{"issue":"3","key":"1896_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/all.13080","volume":"72","author":"T Czarnowicki","year":"2017","unstructured":"Czarnowicki T, Santamaria-Bab\u00ed LF, Guttman-Yassky E. Circulating CLA(+) T cells in atopic dermatitis and their possible role as peripheral biomarkers. Allergy. 2017;72(3):366\u201372.","journal-title":"Allergy"},{"issue":"4","key":"1896_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2024.110870","volume":"116","author":"W Bai","year":"2024","unstructured":"Bai W, Yang L, Qiu J, Zhu Z, Wang S, Li P, et al. Single-cell analysis of CD4+ tissue residency memory cells (TRMs) in adult atopic dermatitis: a new potential mechanism. Genomics. 2024;116(4):110870.","journal-title":"Genomics"},{"issue":"5","key":"1896_CR55","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/ijms27052371","volume":"27","author":"R Dominguez-Lopez","year":"2026","unstructured":"Dominguez-Lopez R, Aranda CJ, G\u00f3mez-de la Fuente E, P\u00e9rez-Garc\u00eda B, Perez-Bootello J, Abbad-Jaime de Aragon C, et al. Memory cells in atopic dermatitis: paving the way to disease modification. Int J Mol Sci. 2026;27(5):2371.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1896_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/all.70061","volume":"81","author":"MS de Bruin-Weller","year":"2026","unstructured":"de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, et al. Biologics to treat atopic dermatitis: effectiveness, safety, and future directions. Allergy. 2026;81(2):326\u201344.","journal-title":"Allergy"},{"issue":"3","key":"1896_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40257-025-00927-x","volume":"26","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D, et al. Real-world evidence of tralokinumab effectiveness and safety: a systematic review and meta-analysis. Am J Clin Dermatol. 2025;26(3):411\u201324.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1896_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000071","volume":"8","author":"Y Watanabe","year":"2023","unstructured":"Watanabe Y, Ishiuji Y, Ogawa-Tominaga M, Katsuta M, Asahina A. Real-world clinical efficacy of nemolizumab in Japanese patients with atopic dermatitis. Itch. 2023;8(4):e0071.","journal-title":"Itch"},{"issue":"4","key":"1896_CR59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40257-026-01033-2","volume":"27","author":"T Hagino","year":"2026","unstructured":"Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, Kanda N. 48-week real-world outcomes of lebrikizumab treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients. Am J Clin Dermatol. 2026;27(4):831\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1896_CR60","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1111\/all.70321","volume":"81","author":"K Thormann","year":"2026","unstructured":"Thormann K, Arms C, Cazzaniga S, Martignoni Z, Lehmann M, Simon HU, et al. An immunologic perspective on adverse reactions observed upon systemic therapies of atopic dermatitis: a retrospective study of 145 cases. Allergy. 2026;81(7):2539\u201343.","journal-title":"Allergy"},{"issue":"1","key":"1896_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1896_CR62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40259-025-00762-w","volume":"40","author":"D Oliveira Dos Santos","year":"2026","unstructured":"Oliveira Dos Santos D, Mohamed A, Mohamed A, Alvarenga JM, Torres T. The role of OX40 pathway inhibition as a new therapeutic strategy for atopic dermatitis. BioDrugs. 2026;40(2):263\u201378.","journal-title":"BioDrugs"},{"key":"1896_CR63","unstructured":"A first-in-human, phase 1a, randomized, double-blind, sponsor-open, placebo-controlled, single ascending dose trial to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06782477. Accessed April 1, 2026."},{"key":"1896_CR64","unstructured":"A phase 2b, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of IMG-007 in adult participants with moderate-to-severe atopic dermatitis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07037901. Accessed April 1, 2026."},{"key":"1896_CR65","unstructured":"A phase 1b, open-label, randomized, multicenter, active comparator study to evaluate the safety, tolerability, and pharmacokinetics of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07027527. Accessed April 1, 2026."},{"key":"1896_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1870289","volume":"17","author":"S Salek-Ardakani","year":"2026","unstructured":"Salek-Ardakani S. Is Kaposi\u2019s sarcoma the end of the OX40\/OX40L axis in atopic dermatitis? Front Immunol. 2026;17:1870289.","journal-title":"Front Immunol"},{"issue":"3","key":"1896_CR67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/antiox15030299","volume":"15","author":"P Lipska","year":"2026","unstructured":"Lipska P, \u0141uka\u0144ko K, Sobczak J, Lazarchuk I, Duda-Madej A. From dysbiosis to inflammation: gut microbiota and oxidative stress in atopic dermatitis. Antioxidants (Basel). 2026;15(3):299.","journal-title":"Antioxidants (Basel)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01896-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:03:18Z","timestamp":1791450198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01896-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01896-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shawn G. Kwatra has received grants as a consultant and\/or advisory board member for Galderma. Emma Guttman-Yassky is an employee of Mount Sinai; this institution has received research grants from LEO Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Myers Squibb, Aslan Pharmaceuticals, Regeneron Pharmaceuticals, AnaptysBio, Concert Pharmaceuticals, Janssen, Q32 Bio, AbbVie, Eli Lilly, Arcutis Biotherapeutics, and Inmagene Biopharmaceuticals. Emma Guttman-Yassky has been a consultant for AbbVie, Arcutis, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Artax Biopharma, Astria Therapeutics, Bristol Myers Squibb, Boehringer Ingelheim, Calliditas Therapeutics, Cara Therapeutics, Celldex Therapeutics, Centrexion Therapeutics, Connect Biopharma, Coty, DBV Technologies, Eli Lilly, Enveda, Escient Pharmaceuticals, Fairmount Funds Management, FL2022-001, Galderma, GateBioscience, GV (Google Ventures), GSK, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, LEO Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis, Numab Therapeutics, Nuvig, OrbiMed, Otsuka, Pfizer, Pharmaxis, Pioneering Medicines, Proteologix, RAPT Therapeutics, RayThera, Regeneron, Ribon Therapeutics, Sagimet Biosciences, Sanofi, Sato Pharmaceutical, Schr\u00f6dinger, Sitryx, Sun Pharma, Takeda Pharmaceutical, Teva Branded Pharmaceutical Products R&D, TRexBio, UCB, and Ventyx Biosciences. John Oppenheimer\u00a0has served as a consultant and adviser for Aimmune Therapeutics, Amgen, ARS Pharmaceuticals, Aquestive Therapeutics, and GSK; on the adjudication and data safety monitoring board for AbbVie, AstraZeneca, GSK, and Sanofi; as a reviewer for UpToDate; and as the executive editor for the\u00a0\n                      Annals of Allergy, Asthma, and Immunology\n                      . Bob Geng has received consulting fees or speaking honoraria from Sanofi, Regeneron, Pfizer, AbbVie, LEO Pharma, Eli Lilly, Novartis, and Incyte and has received research funds from Sanofi, Regeneron, LEO Pharma, Eli Lilly, Novartis, Incyte, and Amgen. Stephan Weidinger has received institutional research grants from LEO Pharma, Pfizer, and Sanofi Deutschland; has consulted for AbbVie, Almirall, Apogee, Boehringer Ingelheim, Eli Lilly, Galderma, Kymab (a Sanofi company), LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and UCB; has lectured at educational events sponsored by AbbVie, Almirall, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi Genzyme; and is involved in clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Tiago Torres has received consulting and speaker\u2019s honoraria from or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, BIOCAD, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung Bioepis, Sanofi Genzyme, Sandoz, and UCB. Ahmed Ameen has received honoraria as a speaker, adviser, consultant, or principal investigator from AbbVie, Ego Pharmaceuticals, Galderma, Johnson & Johnson, LEO Pharma, Eli Lilly, L\u2019Or\u00e9al, NewBridge Pharmaceuticals, Novartis, Organon, Pfizer, and Sanofi. Nicolas Gaudenzio has collaborated with, consulted for, or served on the scientific advisory board of Genoskin, Escient Pharmaceuticals, Aikium, CEVA, MaxiVax, Boehringer Ingelheim, Novartis, Sanofi, and ArgenX. Kassim Rahawi is a former employee and still owns stock and stock options in the company. Chia Hui Chung is an employee of Sanofi and may hold stock and stock options in the company.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain new studies with human participants or animals performed by the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}